glp-1 agonists brands Market to Reach $170.75B by 2033 | Mayuri Lamba posted on the topic America's Poison Centers - GLP-1
Description
The heterogeneity of these findings may be attributed to variations in study design, population characteristics, and the types of drug formulations used [9]

doi: 10.1111/bcp.14091 124 SeinoYFukushimaMYabeDSeinoYFukushimaMYabeD

doi:10.1111/j.1476-5381.2012.01971.x 11

Niswender K., PiSunyer X., Buse J., et al., Weight Change With Liraglutide and Comparator Therapies: An Analysis of Seven Phase 3 Trials From the Liraglutide Diabetes Development Programme, Diabetes, Obesity & Metabolism 15 (2013): 4254

J Neurosci Res (2007) 85(10):2099119
